Shield Therapeutics plc, provides the headline results from the reanalysis of the AEGIS-H2H study. For further details click here.
Back to news6 Aug 2020
Shield Therapeutics plc, provides the headline results from the reanalysis of the AEGIS-H2H study. For further details click here.
Back to news